Literature DB >> 16946008

AKT in thyroid tumorigenesis and progression.

Motoo Shinohara1, Yun Jae Chung, Motoyasu Saji, Matthew D Ringel.   

Abstract

AKT (protein kinase B) is a central signaling molecule in the phosphatidyl inositol 3-kinase pathway that is frequently activated in human cancer. AKT activation regulates energy metabolism, apoptosis, proliferation, and migration in many cell systems. In thyroid cancer, AKT activation is involved in tumorigenesis, particularly in both inherited and sporadic forms of follicular thyroid cancer. Phosphatidyl inositol 3-kinase and AKT signaling also appear to play an important role in progression of both papillary and follicular cancers. In this review, the role of AKT in thyroid cancer development and progression are discussed with a focus on areas of current debate in the literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946008     DOI: 10.1210/en.2006-0937

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  30 in total

1.  The role of PI3K signaling pathway and its associated genes in papillary thyroid cancer.

Authors:  Elham Amjad; Solmaz Asnaashari; Babak Sokouti
Journal:  J Egypt Natl Canc Inst       Date:  2021-05-17

Review 2.  MicroRNAs in thyroid cancer.

Authors:  Albert de la Chapelle; Krystian Jazdzewski
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

3.  MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

Authors:  Christina M Knippler; Motoyasu Saji; Neel Rajan; Kyle Porter; Krista M D La Perle; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

4.  SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.

Authors:  Dawei Sun; Rui Zhou; Huamin Liu; Wenhai Sun; Anbing Dong; Hongmei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.

Authors:  Tania Pilli; Silvia Cantara; Carlotta Marzocchi; Furio Pacini; Bellur S Prabhakar; Maria Grazia Castagna
Journal:  Endocrine       Date:  2019-08-03       Impact factor: 3.633

Review 6.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

7.  Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo.

Authors:  Hanguo Jiang; Desheng Fan; Gengyin Zhou; Xiaofang Li; Huihua Deng
Journal:  J Exp Clin Cancer Res       Date:  2010-04-22

8.  Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway.

Authors:  Shawn D Larson; Lindsey N Jackson; Taylor S Riall; Tatsuo Uchida; Robert P Thomas; Suimin Qiu; B Mark Evers
Journal:  J Am Coll Surg       Date:  2007-02-23       Impact factor: 6.113

9.  PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome.

Authors:  Xin He; Motoyasu Saji; Deepa Radhakrishnan; Todd Romigh; Joanne Ngeow; Qi Yu; Yu Wang; Matthew D Ringel; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-09-07       Impact factor: 5.958

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.